Showing results (41-50 of 57) with videos related to
Sort By:
Pageof 6
Protein Science : a Publication of the Protein Society|December 15, 2022
N-terminal β-strand in YAP is critical for stronger binding to scalloped relative to TEAD transcription factorFedir Bokhovchuk, Yannick Mesrouze, Marco Meyerhofer, et al.Protein Science : a Publication of the Protein Society|November 8, 2019
Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factorsFedir Bokhovchuk, Yannick Mesrouze, Clara Delaunay, et al.Bioorganic & Medicinal Chemistry Letters|August 21, 2016
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argumentPascal Furet, Keiichi Masuya, Joerg Kallen, et al.Breast Cancer Research : BCR|April 24, 2008
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer modelsMichael Rugaard Jensen, Joseph Schoepfer, Thomas Radimerski, et al.Molecular Cancer Therapeutics|April 8, 2010
Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800Andrew J Massey, Joseph Schoepfer, Paul A Brough, et al.Biochemistry|March 8, 2023
Design and Biochemical Characterization of Peptidic Inhibitors of the Myb/p300 InteractionMatthew Jones, Philipp Grosche, Andreas Floersheimer, et al.Scientific Reports|October 16, 2020
A new perspective on the interaction between the Vg/VGLL1-3 proteins and the TEAD transcription factorsYannick Mesrouze, Gustavo Aguilar, Fedir Bokhovchuk, et al.Journal of Medicinal Chemistry|July 17, 2015
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt TumorsPhilipp Holzer, Keiichi Masuya, Pascal Furet, et al.Chemmedchem|August 11, 2022
The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct CompetitionPascal Furet, Vincent Bordas, Mickaël Le Douget, et al.Molecular Cancer Therapeutics|July 9, 2008
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activitySauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, et al.Pageof 6